Support for the Commercialization of Regenerative Medicine Research for Diabetic Nephropathy by ミネルヴァメディカ and Sapporo Medical University

「Going forward, the Company will establish a cell therapy platform for its regenerative medicine business based on the cardiac stem cells of 日本再生医療 and the dental pulp stem cells of セルテクノロジー described above, and pursue various business opportunities, including the development of new products and therapies.」

「In May of the same year, ミネルヴァメディカ, a regenerative medicine venture originating in Hokkaido, was established through joint investment by companies headquartered in Hokkaido, including the Company, and financial institutions. Through the company, the Group is promoting the research and development of a treatment using autologous bone-marrow-derived mesenchymal stem cells for diabetic nephropathy, which is being studied at Sapporo Medical University, steadily expanding and advancing the business.」

「In May of the same year, ミネルヴァメディカ, a regenerative medicine venture originating in Hokkaido, was established through joint investment by companies headquartered in Hokkaido, including the Company, and financial institutions. Through the company, the Group is promoting the research and development of a treatment using autologous bone-marrow-derived mesenchymal stem cells for diabetic nephropathy, which is being studied at Sapporo Medical University, steadily expanding and advancing the business.」

「In May of the same year, ミネルヴァメディカ, a regenerative medicine venture originating in Hokkaido, was established through joint investment by companies headquartered in Hokkaido, including the Company, and financial institutions. The company and Sapporo Medical University also entered into a joint research agreement for a treatment using autologous bone-marrow-derived mesenchymal stem cells for diabetic nephropathy, steadily expanding and advancing the business.」

「In May of the same year, ミネルヴァメディカ, a regenerative medicine venture originating in Hokkaido, was established through joint investment by companies headquartered in Hokkaido and financial institutions. The company and Sapporo Medical University also entered into a joint research agreement for a treatment using autologous bone-marrow-derived mesenchymal stem cells for diabetic nephropathy, steadily expanding and advancing the business.」

「Furthermore, in May of the same year, we established Minerva Medica Co., Ltd., a regenerative medicine venture based in Hokkaido, through a joint investment with a Hokkaido-based company and a financial institution. We also entered into a joint research agreement with the company and Sapporo Medical University for a treatment for diabetic nephropathy using autologous bone marrow-derived mesenchymal stem cells, and are steadily expanding and advancing this business.」